Therapeutic effects of GSK-3β inhibition have been shown in epithelial as well as in hematopoietic, neuronal and musculoskeletal cell malignancies including leukemia [20], glioblastoma [16, 17] and rhabdomyosarcoma [21, 22]. The gene discussed is GSK3B; the disease is glioblastoma.